Does the CYP3A5*3 polymorphism affect in vivo drug elimination?
- 1 October 2003
- journal article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 13 (10) , 585-587
- https://doi.org/10.1097/00008571-200310000-00001
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Pharmacokinetics of Midazolam and 1′-Hydroxymidazolam in Chinese with Different CYP3A5 GenotypesDrug Metabolism and Disposition, 2002
- Genetic contribution to variable human CYP3A-mediated metabolismAdvanced Drug Delivery Reviews, 2002
- Explaining Interindividual Variability of Docetaxel Pharmacokinetics and Pharmacodynamics in Asians Through Phenotyping and Genotyping StrategiesJournal of Clinical Oncology, 2002
- Role of temperature on protein and mRNA cytochrome P450 3A (CYP3A) isozymes expression and midazolam oxidation by cultured rat precision-cut liver slicesBiochemical Pharmacology, 2002
- Co-Regulation of CYP3A4 and CYP3A5 and Contribution to Hepatic and Intestinal Midazolam MetabolismMolecular Pharmacology, 2002
- Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in manXenobiotica, 2002
- In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentrationPharmacogenetics, 2001
- Cloning and Tissue Distribution of a Novel Human Cytochrome P450 of the CYP3A Subfamily, CYP3A43Biochemical and Biophysical Research Communications, 2001
- Role of Cytochrome P450 Enzymes in Drug-Drug InteractionsPublished by Elsevier ,1997
- Molecular basis of polymorphic drug metabolismJournal of Molecular Medicine, 1995